Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
68,014.59 +900.78 (+1.34%) CMC Crypto 200
1,372.40 +41.80 (+3.14%)
Vanda Pharmaceuticals Inc. (0LKB.L)
| Previous close | 6.20 |
| Open | 6.18 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 6.12 - 6.21 |
| 52-week range | 3.30 - 6.88 |
| Volume | |
| Avg. volume | 3,266 |
| Market cap | 317.985M |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | 0.19 |
| EPS (TTM) | 0.32 |
| Earnings date | 31 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireVanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2024 on Wednesday, July 31, 2024, after the market closes.
- PR Newswire
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of Delaware (the "Court") denied the motions for judgment on the pleadings that were filed by Teva Pharmaceuticals USA, Inc. ("Teva") and Apotex Inc. and Apotex Corp. ("Apotex") and ordered that Vanda's HETLIOZ® patent lawsuit may proceed.
- PR Newswire
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board"), following careful review and consultation with its independent financial and legal advisors, has determined that the unsolicited proposal from Cycle Group Holdings Ltd ("Cycle Group") to acquire Vanda for $8.00 per share in cash and the revised unsolicited proposal from Future Pak, LLC ("FP") to acquire Vanda for $8.50-$9.00 per share in cash plus certain Contingent Value Rights
